key: cord-1007329-n6ezaews
authors: Hagman, Karl; Hedenstierna, Magnus; Rudling, Johan; Gille-Johnson, Patrik; Hammas, Berit; Grabbe, Malin; Jakobsson, Jan; Dillner, Joakim; Ursing, Johan
title: Duration of SARS-CoV-2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID-19: a cohort study: Duration of SARS-CoV-2 viremia
date: 2021-11-17
journal: Diagn Microbiol Infect Dis
DOI: 10.1016/j.diagmicrobio.2021.115595
sha: 2b873c3e9bf32502ca331003e1f562390e5476e3
doc_id: 1007329
cord_uid: n6ezaews

BACKGROUND: SARS-CoV-2 viremia at admission is associated with high risk for mortality. However, longitudinal data on viremia duration are limited. METHODS: Viremic patients hospitalized for COVID-19 were included in a cohort. Time to serum viral clearance and the effect of viremia duration on the odds of mortality were calculated. RESULTS: 121 viremic patients were included. Median age was 62 (IQR 52-71) years and 68% were males. The total in-hospital mortality of the cohort was 33%. Median time from admission to serum viral clearance was 7 (95% CI 6-8) days. Duration of viremia showed a relative risk ratio of 1.40 (95% CI 1.02-1.92) for the odds of mortality in an adjusted multinomial logistic regression. Serum viral clearance coincided with defervescence and decreasing C-reactive protein. CONCLUSIONS: Median time to serum viral clearance was 7 days after admission. The odds of mortality increased with 40% for each additional day of viremia.

males. The total in-hospital mortality of the cohort was 33%. Median time from admission to 45 serum viral clearance was 7 (95% CI 6-8) days. Duration of viremia showed a relative risk 46 ratio of 1.40 (95% CI 1.02-1.92) for the odds of mortality in an adjusted multinomial logistic 47 5 least one positive serum SARS-CoV-2 RT-PCR were eligible for inclusion. The study period 98 was April 1 to September 5, 2020. 99

During the study period a phase I/II convalescent plasma study for hospitalized patients, and 100 a study investigating inhaled nitric oxide for mechanically ventilated patients was conducted. 101

Hospitalized COVID-19 patients routinely received prophylaxis for thromboembolism during 102 the study period. Corticosteroid treatment was given routinely from 18 th of June to patients 103 requiring oxygen therapy. Remdesivir treatment was given to moderately/critically ill patients 104 with viremia from 29 th of June. No other COVID-19 specific treatments were used. A 105 proportion of the data (61/439 analyzed serum samples) was previously published in an 106 article regarding viremia at admission as a predictor for mortality (Hagman et al., 2020). 107 108 2.2 Serum sampling 109

The beginning of the study period coincided with the first peak of the COVID-19 epidemic. 110

During this period patients were admitted to different wards throughout the hospital. There 111 were no particular criteria for admission to the department of infectious diseases. During this 112 period, only more severely ill patients admitted to the department of infectious diseases were 113 tested for SARS-CoV-2 RNA in serum, at the discretion of the treating physician. From the 114 10 th of May, patients treated for COVID-19 at the department of infectious diseases and the 115 ICU were routinely tested for SARS-CoV-2 in serum every 1-3 days until serum viral 116 clearance. Sampling at other wards was done sporadically throughout the study period. 117

Serum viral clearance was defined as two consecutive negative serum samples or one 118 negative serum sample when no more sampling was done. The timepoint for serum viral 119 clearance was subsequently defined as the day after the last positive serum sample as the 120 interval between samplings could vary by a number of days. Duration of viremia was defined 121 as the number of days from admission to serum viral clearance. 122 6 123

Data collection was retrospective. RT-PCR results were collected from the microbiological 125 laboratory at Karolinska University Hospital. Patient characteristics and outcome data were 126 collected from electronic medical records. Laboratory sampling was irregular at non-ICU 127 wards, but daily and extensive at the ICU. Therefore, only peak body temperature and C-128 reactive protein (CRP) were recorded serially seven days before and after serum viral Table 1 . 186

The median time to first serum sample was 1 (IQR 1-2) day after admission, corresponding to 187 9 (IQR 8-12) days after symptom onset. A total of 439 serum samples were included with a 188 median of 3 (IQR 2-5) serum samples per patient resulting in a median of 2 (IQR 1-3) (Table 2) . 207

The results were consistent in sensitivity analyses where serum viral clearance was defined as 208 the day of the first negative serum sample, and viremia duration defined as number of days 209 from first to last positive serum sample (Supplementary table 3 and 4) . The main results from this study was presented at the ECCMID-conference 2021. 302 303 

Oxygen demand, L/min